EVMN Stock Catalyst: Evommune Reports Top-Line Results from Phase 2a Trial of EVO301

Feb 9, 2026 · 3:59pm ET

The trial was randomized, double-blind, and placebo-controlled.

Max move

+123.0%

High of day $38.00

Sparker timei

3:59pm ET

EVMN · Feb 9, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Evommune, Inc. (NYSE: EVMN) announced the top-line results from its Phase 2a trial of EVO301. The trial, which was randomized, double-blind, and placebo-controlled, aimed to evaluate the efficacy and safety of EVO301 in the treatment of a specific condition.

Details of the trial outcomes, including efficacy data and safety profiles, were disclosed. The company plans to further analyze the data and determine next steps for the development of EVO301.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time EVMN sparks.

Download Sniper App →

Catch the next EVMN-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →